Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting ...

Children should have the freedom to focus on school, friendships, family, sports, birthdays, and simply growing up. Yet ...

Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech ...

Discovery remains essential, but its value depends on builders and systems capable of carrying it through. The organizations ...

Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to ...

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but ...

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli ...

The government has announced “most-favored-nation” pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s spending on prescription drugs.

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the ...

In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato ...

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in ...

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.